Lista de obras - Floriana Morgillo - Dominio Público Uruguay

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer.

artículo científico publicado en 2011

A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial

artículo científico publicado en 2014

A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics.

artículo científico publicado en 2007

AXL is an oncotarget in human colorectal cancer.

artículo científico publicado en 2015

Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.

artículo científico publicado en 2005

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors

artículo científico publicado en 2011

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.

artículo científico publicado en 2017

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

artículo científico publicado en 2011

Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.

artículo científico publicado en 2010

Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials.

artículo científico publicado en 2011

Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication

scientific article published on 16 December 2011

Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases

artículo científico publicado en 2013

Critical appraisal of the use of regorafenib in the management of colorectal cancer.

artículo científico publicado en 2013

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer

artículo científico publicado en 2017

Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study

artículo científico publicado en 2014

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR

artículo científico publicado en 2017

Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma

artículo científico publicado en 2004

Erlotinib in cancer treatment.

artículo científico publicado en 2007

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

artículo científico publicado en 2012

Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab

artículo científico publicado en 2022

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

artículo científico publicado en 2006

Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.

artículo científico publicado en 2005

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.

artículo científico publicado en 2016

Implication of the Hedgehog pathway in hepatocellular carcinoma.

artículo científico publicado en 2017

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

artículo científico publicado en 2009

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

artículo científico publicado en 2013

Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer

scientific article published on 01 September 2020

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells ⬇️

artículo científico publicado el 8 de mayo de 2012

Lonafarnib in cancer therapy.

artículo científico publicado en 2006

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models

artículo científico publicado en 2015

Metformin in lung cancer: rationale for a combination therapy

artículo científico publicado en 2013

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells

artículo científico publicado en 2015

Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer.

artículo científico publicado en 2014

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care.

artículo científico publicado en 2007

Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).

artículo científico publicado en 2004

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.

artículo científico publicado en 2017

Preoperative chemo-radiotherapy for carcinoma of the esophagus

artículo científico publicado en 2001

Preoperative treatment of locally advanced esophageal carcinoma (Review).

artículo científico publicado en 2013

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets

artículo científico publicado en 2017

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.

artículo científico publicado en 2015

Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.

artículo científico publicado en 2014

Primary pleural squamous cell carcinoma: A diagnostic challenge

artículo científico publicado en 2017

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.

artículo científico publicado en 2015

Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer

artículo científico publicado en 2012

Role and targeting of anaplastic lymphoma kinase in cancer

artículo científico publicado en 2018

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents

artículo científico publicado en 2015

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

artículo científico publicado en 2015

Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.

artículo científico publicado en 2008

Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer

artículo científico publicado en 2013

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review

scientific article published on 18 October 2016

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

artículo científico publicado en 2013

Targeting EGFR in pancreatic cancer treatment.

artículo científico publicado en 2012

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

artículo científico publicado en 2008

The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion.

artículo científico publicado en 2012

Therapies in the pipeline for small-cell lung cancer.

artículo científico publicado en 2016

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology

artículo científico publicado en 2013

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

artículo científico

Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis

artículo científico publicado en 2019

Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications

artículo científico publicado en 2010

Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study

artículo científico publicado en 2010

Lista de obras de Floriana Morgillo

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer.

A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial

A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics.

AXL is an oncotarget in human colorectal cancer.

Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.

Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials.

Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication

Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases

Critical appraisal of the use of regorafenib in the management of colorectal cancer.

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer

Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR

Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma

Erlotinib in cancer treatment.

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.

Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.

Implication of the Hedgehog pathway in hepatocellular carcinoma.

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells ⬇️

Lonafarnib in cancer therapy.

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models

Metformin in lung cancer: rationale for a combination therapy

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells

Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer.

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care.

Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.

Preoperative chemo-radiotherapy for carcinoma of the esophagus

Preoperative treatment of locally advanced esophageal carcinoma (Review).

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.

Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.

Primary pleural squamous cell carcinoma: A diagnostic challenge

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.

Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer

Role and targeting of anaplastic lymphoma kinase in cancer

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.

Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

Targeting EGFR in pancreatic cancer treatment.

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion.

Therapies in the pipeline for small-cell lung cancer.

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis

Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications

Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study